Teladoc Health reported third‑quarter 2025 results with consolidated revenue of $626.4 million, a 2.2% year‑over‑year decline from $640.5 million in Q3 2024. The company posted a net loss of $49.5 million, or $0.28 per share, and adjusted EBITDA of $69.9 million, down 16% from $83.3 million in the prior year. A $12.6 million goodwill impairment related to the acquisition of Telecare Australia Pty Ltd contributed to the loss.
Integrated Care revenue rose 2% to $389.5 million, generating adjusted EBITDA of $66.1 million and a 17.0% margin. BetterHelp revenue fell 8% to $236.9 million, with adjusted EBITDA of $3.8 million and a 1.6% margin. The decline in BetterHelp was driven by intensified competition and a post‑pandemic shift in the direct‑to‑consumer mental‑health market.
Cash and cash equivalents stood at $726.2 million at the end of Q3 2025, down from $1.2 billion a year earlier, reflecting ongoing capital deployment and the goodwill impairment charge.
Teladoc guided for fourth‑quarter revenue of $622 million to $652 million, with a midpoint of $637 million. Full‑year 2025 revenue guidance is $2.51 billion to $2.53 billion, and net‑loss per share guidance is $-1.25 to $-1.10. Management highlighted continued investment in Integrated Care, expansion of insurance acceptance for BetterHelp, and the rollout of AI‑enabled clinical interventions.
CEO Chuck Divita noted that more than 100 million people have access to Teladoc’s services and emphasized the company’s focus on strategic priorities. CFO Mala Murthy announced her departure after serving since 2019, and the company is in the process of selecting a successor.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.